Nothing Special   »   [go: up one dir, main page]
Skip to main content
Springer Nature Link
Log in

Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

To compare plasma lysophosphatidic acid (LPA) levels in ovarian cancer patients in women with benign ovarian tumors and in women with no ovarian pathology. We correlated clinico-pathological parameters with plasma LPA levels. Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 159 patients (81 patients with ovarian cancer, 27 women without ovarian or uterine pathologies, and 51 patients with benign ovarian tumors) during a 5-year period. Patients with ovarian cancer had a significantly higher plasma LPA level (n = 81; median (med), 11.53 μmol/l; range, 1.78–43.21 μmol/l) compared with controls with no ovarian pathology (n = 27; med, 1.86 μmol/l; range, 0.94–9.73 μmol/l), and patients with benign ovarian tumor (n = 51; med, 6.17 μmol/l; range, 1.12–25.23 μmol/l; P < 0.001). We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics stage. The histological subtype and grade of ovarian cancer did not influence the plasma LPA levels in this study. The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Schwartz PE, Taylor KJ. Is early detection of ovarian cancer possible? An Med. 1995;27:519–28.

    Article  CAS  Google Scholar 

  2. Mills GB, May C, McGill M, et al. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 1988;48:1066–71.

    CAS  PubMed  Google Scholar 

  3. Fishman DA, Bozorgi K. The scientific basis of early detection of epithelial ovarian cancer: The National Ovarian Cancer Early Detection Program [NOCEDP]. Cancer Treat Res. 2002;107:3–28.

    CAS  PubMed  Google Scholar 

  4. Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002;23:57–64.

    Google Scholar 

  5. So J, Navari J, Wang FO, Fishman DA. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynec Oncol. 2004;95:314–22.

    Article  CAS  Google Scholar 

  6. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, et al. Electrospray ionization spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant versus nonmalignant ascitic fluids. Anal Biochem. 2001;290:302–13.

    Article  CAS  PubMed  Google Scholar 

  7. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2006;93:762–8.

    Google Scholar 

  8. Lee Z, Swaby FR, Liang Y, Yu S, Liu S, Lu KH, et al. Lysophophatidic Acid Is a Major Regulator of Growth-Regulated Oncogene in Ovarian Cancer. Cancer Res. 2006;66:2740–8.

    Article  CAS  PubMed  Google Scholar 

  9. Fujita T, Miyamoto S, Onoyama I, et al. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophopsphatidic acid in the development of human ovarian cancer. Cancer Lett. 2003;192:161–9.

    Article  CAS  PubMed  Google Scholar 

  10. Wang P, Wu X, Chen W, Liu J, Wang X. The lysophosphatidic acid [LPA] receptors their expression and significance in epithelial ovarian neoplasms. Gynec Oncol. 2007;104:714–20.

    Article  CAS  Google Scholar 

  11. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid [LPA]-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res. 2000;6:2482–91.

    CAS  PubMed  Google Scholar 

  12. Ozols RF, Rubin SC, Thomas G, Robboy S. Asdf. In: Hoskins WJ, Perez CA, Zouny RC, editors. Epithelial ovarian cancer. Principles and practisse of gynecologic oncology. Philadelphia: Lippincott-Raven; 1997. p. 958.

    Google Scholar 

  13. WHO. WHO Handbook for reporting results of cancer treatment. Geneva: WHO; 1979.

    Google Scholar 

  14. Sutphen R, Xu Y, Wilbanks D, Fiorica J, Grendys Jr EC, La Polla JP, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidem. 2004;13:1185–91.

    CAS  Google Scholar 

  15. Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylicholine in ovarian cancer patients. Int J Cancer. 1997;71:31–4.

    Article  CAS  PubMed  Google Scholar 

  16. Yan Xu, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719–23.

    Article  Google Scholar 

  17. Sedláková I, Vávrová J, Tošner J, Hanousek L. Lysophosphatidic acid in ovarian cancer patients. Česká gynekologie. 2006;71:312–7.

    PubMed  Google Scholar 

  18. Baker DL, Morrison P, Miller B, Riely CA, Tolley B, Westermann AM, et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA. 2002;287:3081–2.

    Article  PubMed  Google Scholar 

  19. Pozlep B, Meleh M, Kobal B, et al. Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors. Eur J Gynaecol Oncol. 2007;28:394–9.

    CAS  PubMed  Google Scholar 

  20. So J, Wang F, Navari J, Schreher J, Fishman DA. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynec Oncol. 2005;97:870–8.

    CAS  Google Scholar 

Download references

Acknowledgments

This project was supported by the Ministry of Health Grant Agency, No. 97373.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, University Hospital, Sokolská 581, 500 05, Hradec Králové, Czech Republic

    Iva Sedláková & Jindřich Tošner

  2. Department of Clinical Biochemistry, University Hospital, Hradec Králové, Czech Republic

    Jaroslava Vávrová

  3. Department of Gynecology and Obstetrics, Hospital Pardubice, Pardubice, Czech Republic

    Ladislav Hanousek

Authors
  1. Iva Sedláková
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaroslava Vávrová
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jindřich Tošner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ladislav Hanousek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Iva Sedláková.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sedláková, I., Vávrová, J., Tošner, J. et al. Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer. Tumor Biol. 32, 311–316 (2011). https://doi.org/10.1007/s13277-010-0123-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-010-0123-8

Keywords

Search

Navigation